Jfl Life Sciences bulk deals
NSE: JFLLIFEPharmaceuticals & Biotechnology
Last close ₹10.30down ₹0.50 (4.63%)
Share price at the NSE close on 22 Oct 2026. Previous close ₹10.80.
52-week range of traded prices to 22 Oct 2026
₹8.55Low, 30 Mar 2026₹15.40High, 24 Dec 2025
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹34 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 0.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 15.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,000100.0% delivered
Jfl Life Sciences bulk deals
None in the last 12 months, since 23 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Wednesday 25 Sep 20241 firm · ₹0.15 Cr bought · ₹0 soldNet bought ₹0.15 Cr
- BoughtNATHABHAI BHIKHABHAI PATEL HUFBought 60,000 at ₹24.500.18% of the company₹0.15 Cr
Tuesday 24 Sep 20243 firms · ₹0.22 Cr bought · ₹0.45 Cr soldNet sold ₹0.22 Cr
- BoughtMULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBought 96,000 at ₹23.350.29% of the company₹0.22 Cr
- SoldPRATIK RAJENDRA GANDHISold 96,000 at ₹23.350.29% of the company₹0.22 Cr
- SoldPRATIK RAJENDRABHAI GANDHISold 96,000 at ₹23.350.29% of the company₹0.22 Cr
BonusEach share became 3 on 24 Sep 2024. The lines below are on the share count before it.
Friday 5 Jul 20241 firm · ₹0.35 Cr bought · ₹0.23 Cr soldNet bought ₹0.12 Cr
- Both waysAMRITA JAINBought 60,000 at ₹58.21Sold 40,000 at ₹57.850.55% of the companyNet +20,000 shares₹0.35 Cr bought
Monday 24 Jul 20231 firm · ₹0.37 Cr bought · ₹0.33 Cr soldNet bought ₹0.04 Cr
- Both waysMITTAL RIMPYBought 72,000 at ₹51.76Sold 64,000 at ₹51.930.65% of the companyNet +8,000 shares₹0.37 Cr bought
Friday 21 Jul 20231 firm · ₹0.37 Cr bought · ₹0.38 Cr soldNet nil
- Both waysMITTAL RIMPYBought 76,000 at ₹49.26Sold 76,000 at ₹49.880.69% of the companyNet nil₹0.37 Cr bought
Wednesday 4 Jan 20232 firms · ₹0.27 Cr bought · ₹0.27 Cr soldNet nil
- SoldECONO BROKING PRIVATE LIMITEDSold 58,000 at ₹46.110.53% of the company₹0.27 Cr
- BoughtLINTON TRADERS PRIVATE LIMITEDBought 58,000 at ₹46.110.53% of the company₹0.27 Cr
Wednesday 21 Sep 20221 firm · ₹0 bought · ₹0.31 Cr soldNet sold ₹0.31 Cr
- SoldVINOD SHANKARSold 62,000 at ₹50.79₹0.31 Cr
Thursday 15 Sep 20221 firm · ₹0 bought · ₹0.43 Cr soldNet sold ₹0.43 Cr
- SoldMULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDSold 76,000 at ₹56.75₹0.43 Cr
Wednesday 14 Sep 20221 firm · ₹0.74 Cr bought · ₹0 soldNet bought ₹0.74 Cr
- BoughtMULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBought 1,36,000 at ₹54.20₹0.74 Cr
Thursday 8 Sep 20227 firms · ₹3.14 Cr bought · ₹0 soldNet bought ₹3.14 Cr
- BoughtAMI KALPESH SHAHBought 64,000 at ₹70.00₹0.45 Cr
- BoughtBHAVESH MAHENDRABHAI SHAHBought 64,000 at ₹70.00₹0.45 Cr
- BoughtDEEPA DHARMESH SHAHBought 64,000 at ₹70.00₹0.45 Cr
- BoughtKALPESH JASVANTLAL SHAHBought 64,000 at ₹70.00₹0.45 Cr
- BoughtPRACHI BHAVESH SHAHBought 64,000 at ₹70.00₹0.45 Cr
- BoughtSHAH DHARMESH JASWANTLALBought 64,000 at ₹70.00₹0.45 Cr
- BoughtSHAH REKHABEN MAHENDRABought 64,000 at ₹70.00₹0.45 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 20 deals on record since listing on 8 Sep 2022.